These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 26462195

  • 1. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
    Robinson SJ, Petzer JP, Terre'Blanche G, Petzer A, van der Walt MM, Bergh JJ, Lourens AC.
    Eur J Med Chem; 2015 Nov 02; 104():177-88. PubMed ID: 26462195
    [Abstract] [Full Text] [Related]

  • 2. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR, Shook BC, Rassnick S, Jackson PF, Rhodes K, Drinkenburg WH, Ahnaou A, Te Riele P, Langlois X, Hrupka B, De Haes P, Hendrickx H, Aerts N, Hens K, Wellens A, Vermeire J, Megens AA.
    ACS Chem Neurosci; 2014 Oct 15; 5(10):1005-19. PubMed ID: 25203719
    [Abstract] [Full Text] [Related]

  • 3. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.
    Squarcialupi L, Colotta V, Catarzi D, Varano F, Betti M, Varani K, Vincenzi F, Borea PA, Porta N, Ciancetta A, Moro S.
    Eur J Med Chem; 2014 Sep 12; 84():614-27. PubMed ID: 25063944
    [Abstract] [Full Text] [Related]

  • 4. Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists.
    Robinson SJ, Petzer JP, Rousseau AL, Terre'Blanche G, Petzer A, Lourens ACU.
    Bioorg Med Chem Lett; 2016 Feb 01; 26(3):734-738. PubMed ID: 26776359
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. C2-substituted quinazolinone derivatives exhibit A1 and/or A2A adenosine receptor affinities in the low micromolar range.
    Pieterse L, van der Walt MM, Terre'Blanche G.
    Bioorg Med Chem Lett; 2020 Aug 15; 30(16):127274. PubMed ID: 32631506
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.
    Shook BC, Rassnick S, Wallace N, Crooke J, Ault M, Chakravarty D, Barbay JK, Wang A, Powell MT, Leonard K, Alford V, Scannevin RH, Carroll K, Lampron L, Westover L, Lim HK, Russell R, Branum S, Wells KM, Damon S, Youells S, Li X, Beauchamp DA, Rhodes K, Jackson PF.
    J Med Chem; 2012 Feb 09; 55(3):1402-17. PubMed ID: 22239465
    [Abstract] [Full Text] [Related]

  • 11. 2-Benzylidene-1-Indanone Analogues as Dual Adenosine A1/A2a Receptor Antagonists for the Potential Treatment of Neurological Conditions.
    van Rensburg HJ, Legoabe L, Terre'Blanche G, Van der Walt M.
    Drug Res (Stuttg); 2019 Jul 09; 69(7):382-391. PubMed ID: 30616250
    [Abstract] [Full Text] [Related]

  • 12. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
    Shook BC, Rassnick S, Osborne MC, Davis S, Westover L, Boulet J, Hall D, Rupert KC, Heintzelman GR, Hansen K, Chakravarty D, Bullington JL, Russell R, Branum S, Wells KM, Damon S, Youells S, Li X, Beauchamp DA, Palmer D, Reyes M, Demarest K, Tang Y, Rhodes K, Jackson PF.
    J Med Chem; 2010 Nov 25; 53(22):8104-15. PubMed ID: 20973483
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of 2-benzylidene-1-tetralone derivatives as antagonists of A1 and A2A adenosine receptors.
    Legoabe LJ, Van der Walt MM, Terre'Blanche G.
    Chem Biol Drug Des; 2018 Jan 25; 91(1):234-244. PubMed ID: 28734058
    [Abstract] [Full Text] [Related]

  • 14. The adenosine A(2A) antagonistic properties of selected C8-substituted xanthines.
    Van der Walt MM, Terre'Blanche G, Petzer A, Lourens AC, Petzer JP.
    Bioorg Chem; 2013 Aug 25; 49():49-58. PubMed ID: 23892098
    [Abstract] [Full Text] [Related]

  • 15. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.
    Yang Z, Li X, Ma H, Zheng J, Zhen X, Zhang X.
    Bioorg Med Chem Lett; 2014 Jan 01; 24(1):152-5. PubMed ID: 24332624
    [Abstract] [Full Text] [Related]

  • 16. Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists.
    Varano F, Catarzi D, Falsini M, Vincenzi F, Pasquini S, Varani K, Colotta V.
    Bioorg Med Chem; 2018 Jul 23; 26(12):3688-3695. PubMed ID: 29880250
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and Structure Activity Relationships of Chalcone based Benzocycloalkanone Derivatives as Adenosine A1 and/or A2A Receptor Antagonists.
    Janse van Rensburg HD, Legoabe LJ, Terre'Blanche G.
    Drug Res (Stuttg); 2020 Jun 23; 70(6):243-256. PubMed ID: 32349128
    [Abstract] [Full Text] [Related]

  • 18. Benzopyrone represents a privilege scaffold to identify novel adenosine A1/A2A receptor antagonists.
    van der Walt MM, Terre'Blanche G.
    Bioorg Chem; 2018 Apr 23; 77():136-143. PubMed ID: 29353730
    [Abstract] [Full Text] [Related]

  • 19. Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening.
    Tian S, Wang X, Li L, Zhang X, Li Y, Zhu F, Hou T, Zhen X.
    J Chem Inf Model; 2017 Jun 26; 57(6):1474-1487. PubMed ID: 28463561
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.